Pioneering the development
of engineered IgM antibodies
for the treatment of cancer
Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies
November 22, 2019
November, 2019 – PEGS Europe, Lisbon Bruce Keyt, PhD, Chief Scientific Officer IGM Biosciences, Inc.,…
A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions
November 21, 2019
November, 2019 – PEGS Europe, Lisbon Daniel Chen, MD, PhD, Chief Medical Officer IGM Biosciences,…
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 12, 2019
MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…
IGM Biosciences Announces Third Quarter 2019 Financial Results
November 7, 2019
MOUNTAIN VIEW, Calif., — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…
IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma
October 2, 2019
MOUNTAIN VIEW, Calif., Oct. 02, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on…
IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 20, 2019
MOUNTAIN VIEW, Calif., Sept. 20, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the…